This study aims to present longitudinal changes in Functional Assessment of Cancer Therapy–Prostate (FACT–P) scores during 25–week treatment with enzalutamide or placebo in men with progressive metastatic castration–resistant prostate cancer (mCRPC) after chemotherapy in the AFFIRM trial.

In men with progressive mCRPC after docetaxel–based chemotherapy, enzalutamide is superior to placebo in health–related quality of life outcomes, regardless of analysis model or threshold selected for meaningful response.

READ FULL ARTICLE Curated publisher From Mdlinx